Kailera Pipeline Update: Injectable Ribupatide in Global Phase 3, Oral KAI-7535 in Global Phase 2, Both Licensed From Hengrui
Kailera Therapeutics (NASDAQ: KLRA) holds rights outside Greater China to several Hengrui Pharma obesity drugs. Ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP dual agonist, is in the three-trial global KaiNETIC Phase 3 program, which had enrolled more than 4,700 participants as of August 12, 2026, testing doses up to 10 mg over 76 weeks with data expected in 2028. KAI-7535 (HRS-7535) is a separate drug, a once-daily oral small-molecule GLP-1 receptor agonist, now in a roughly 320-person global Phase 2 trial in the U.S. and Australia with data expected in 2027; Kailera's GLP-1/GIP/glucagon triple agonist is a third drug, HRS-4729.